Micah has over 10 years’ experience applying chemoproteomics to covalent drug discovery. Prior to joining Monimoi, he led the Platform Technology group at Lundbeck La Jolla Research Center where he developed a residue agnostic covalent drug discovery platform leading to multiple pipeline projects. Prior to that, he led Abide Therapeutics’ Chemoproteomics group, designing serine-targeting covalent libraries and industrializing ABPP assays for hit discovery and optimization, supporting the nomination of four covalent clinical candidates. Micah completed his PhD in Medicinal Chemistry from the University of Kansas and a Postdoctoral Fellowship at The Scripps Research Institute in Chemical Biology.